MA28981B1 - Anticorps monoclonaux humains diriges contre l'il-4 humaine - Google Patents

Anticorps monoclonaux humains diriges contre l'il-4 humaine

Info

Publication number
MA28981B1
MA28981B1 MA29708A MA29708A MA28981B1 MA 28981 B1 MA28981 B1 MA 28981B1 MA 29708 A MA29708 A MA 29708A MA 29708 A MA29708 A MA 29708A MA 28981 B1 MA28981 B1 MA 28981B1
Authority
MA
Morocco
Prior art keywords
human
monoclonal antibodies
antibodies against
human monoclonal
against human
Prior art date
Application number
MA29708A
Other languages
English (en)
Inventor
Herrera Jose M Carballido
Vries Jan E De
Christoph Schwaerzler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28981(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0417301A external-priority patent/GB0417301D0/en
Priority claimed from GB0417305A external-priority patent/GB0417305D0/en
Priority claimed from GB0417302A external-priority patent/GB0417302D0/en
Priority claimed from GB0417303A external-priority patent/GB0417303D0/en
Priority claimed from GB0417304A external-priority patent/GB0417304D0/en
Priority claimed from GB0417306A external-priority patent/GB0417306D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28981B1 publication Critical patent/MA28981B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des anti-corps spécifiques de l'interleukine-4 humaine et leur utilisation dans le traitement de IL-4 et/ou de maladies à médiation IgE.
MA29708A 2004-08-03 2007-02-22 Anticorps monoclonaux humains diriges contre l'il-4 humaine MA28981B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0417301A GB0417301D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417305A GB0417305D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417302A GB0417302D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417303A GB0417303D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417304A GB0417304D0 (en) 2004-08-03 2004-08-03 Organic compounds
GB0417306A GB0417306D0 (en) 2004-08-03 2004-08-03 Organic compounds

Publications (1)

Publication Number Publication Date
MA28981B1 true MA28981B1 (fr) 2007-11-01

Family

ID=35457817

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29708A MA28981B1 (fr) 2004-08-03 2007-02-22 Anticorps monoclonaux humains diriges contre l'il-4 humaine

Country Status (29)

Country Link
US (2) US7740843B2 (fr)
EP (2) EP2327726A3 (fr)
JP (1) JP4808712B2 (fr)
KR (1) KR101245996B1 (fr)
CN (1) CN101001877B (fr)
AR (1) AR050044A1 (fr)
AU (1) AU2005268932B2 (fr)
BR (1) BRPI0514124B8 (fr)
CA (1) CA2574289C (fr)
CY (1) CY1115524T1 (fr)
DK (1) DK1817343T3 (fr)
EC (1) ECSP077222A (fr)
ES (1) ES2504415T3 (fr)
HK (1) HK1109158A1 (fr)
HR (1) HRP20140888T1 (fr)
IL (1) IL180789A (fr)
MA (1) MA28981B1 (fr)
MX (1) MX2007001342A (fr)
MY (1) MY141851A (fr)
NO (1) NO20070854L (fr)
NZ (1) NZ552637A (fr)
PE (1) PE20060560A1 (fr)
PL (1) PL1817343T3 (fr)
PT (1) PT1817343E (fr)
SG (1) SG155177A1 (fr)
SI (1) SI1817343T1 (fr)
TN (1) TNSN07036A1 (fr)
TW (1) TWI356828B (fr)
WO (1) WO2006013087A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868647A4 (fr) * 2005-03-24 2009-04-01 Millennium Pharm Inc Anticorps se liant à ov064 et leurs méthodes d'utilisation
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2009005673A1 (fr) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
EP2670776B1 (fr) 2011-02-04 2018-11-21 F. Hoffmann-La Roche AG Variantes génétiques de fc et leurs procédés de production
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业（上海）股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用
US20200158716A1 (en) * 2017-07-17 2020-05-21 Massachusetts Institute Of Technology Cell atlas of healthy and diseased barrier tissues
WO2019028367A1 (fr) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles active
WO2020180727A1 (fr) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN117327181A (zh) * 2020-06-22 2024-01-02 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
CA3241374A1 (fr) 2021-12-30 2023-07-06 Gregory GEBA Methodes pour attenuer la marche atopique par administration d'un antagoniste d'il-4/il-13

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0327283B1 (fr) 1988-02-02 1993-08-18 Schering Biotech Corporation Méthode visant à réduire la réponse immunitaire à l'immunoglobuline E
CA2071908C (fr) * 1989-12-20 2002-04-30 Lata Ramanathan Anticorps antagonistes de l'interleukine-4 humaines
ES2121078T3 (es) 1992-02-19 1998-11-16 Schering Corp Clonacion y expresion de anticuerpos monoclonales humanizados contra interleuquina-4 humana.
DK0671933T3 (da) 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
ATE286510T1 (de) 1993-09-07 2005-01-15 Smithkline Beecham Corp In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US20020002132A1 (en) 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
ATE527278T1 (de) 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine

Also Published As

Publication number Publication date
PT1817343E (pt) 2014-09-09
CY1115524T1 (el) 2017-01-04
HK1109158A1 (en) 2008-05-30
IL180789A (en) 2017-01-31
BRPI0514124B8 (pt) 2021-05-25
BRPI0514124A (pt) 2008-05-27
US7740843B2 (en) 2010-06-22
EP2327726A3 (fr) 2012-07-11
TWI356828B (en) 2012-01-21
PE20060560A1 (es) 2006-06-27
EP2327726A2 (fr) 2011-06-01
SI1817343T1 (sl) 2014-09-30
US20080241160A1 (en) 2008-10-02
JP2008507985A (ja) 2008-03-21
ECSP077222A (es) 2007-03-29
MX2007001342A (es) 2007-04-02
DK1817343T3 (da) 2014-09-15
HRP20140888T1 (hr) 2014-10-24
AU2005268932B2 (en) 2009-06-25
WO2006013087A8 (fr) 2007-03-01
PL1817343T3 (pl) 2014-11-28
AR050044A1 (es) 2006-09-20
WO2006013087A1 (fr) 2006-02-09
AU2005268932A1 (en) 2006-02-09
SG155177A1 (en) 2009-09-30
ES2504415T3 (es) 2014-10-08
CA2574289A1 (fr) 2006-02-09
KR20070047299A (ko) 2007-05-04
TW200617024A (en) 2006-06-01
MY141851A (en) 2010-07-16
EP1817343A1 (fr) 2007-08-15
NO20070854L (no) 2007-04-24
NZ552637A (en) 2010-02-26
US20100254993A1 (en) 2010-10-07
IL180789A0 (en) 2007-06-03
EP1817343B1 (fr) 2014-06-25
CN101001877A (zh) 2007-07-18
JP4808712B2 (ja) 2011-11-02
BRPI0514124B1 (pt) 2017-01-31
CA2574289C (fr) 2014-09-16
TNSN07036A1 (en) 2008-06-02
KR101245996B1 (ko) 2013-03-20
CN101001877B (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
MA28981B1 (fr) Anticorps monoclonaux humains diriges contre l'il-4 humaine
FR22C1052I2 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
MA30041B1 (fr) Immunoglobulines
MA31312B1 (fr) Anticorps anti-ige apoptopiques
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
NO20044462L (no) Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
MA37945B1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
MA33381B1 (fr) Proteine de liaison a il-13
MA28969B1 (fr) Aptameres de liaison a la famille des cytokines de l'il-12 humaine et leur utilisation comme agents therapeutiques de maladies auto-immunes
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
MA29625B1 (fr) Immunoglobulines
FR2889068B1 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
AU2003278497A8 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
AU2003260301A8 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2004005540A3 (fr) Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses
BRPI0414688A (pt) tratamento de doença respiratória com anti-receptor de il-2
WO2004113386A3 (fr) Protéines d'hirudine modifiée et épitopes de lymphocytes t dans l'hirudine
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
ATE456573T1 (de) Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen
PT1496884E (pt) Associacao de um antitrombotico e de aspirina e sua utilizacao no tratamento das doencas tromboticas aterosclerosas.